REPLIGEN CORP Interest Expense Nonoperating
REPLIGEN CORP (RGEN) reported Interest Expense Nonoperating of $5.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-07-29
- REPLIGEN CORP interest expense nonoperating for the quarter ending 2026-06-30 was $5.66M, a 5.77% increase year-over-year.
- REPLIGEN CORP interest expense nonoperating for the quarter ending 2026-03-31 was $5.58M, a 6.25% increase year-over-year.
- REPLIGEN CORP interest expense nonoperating for the quarter ending 2025-12-31 was $5.50M, a 0.60% increase year-over-year.
- REPLIGEN CORP interest expense nonoperating for the quarter ending 2025-09-30 was $5.41M, a 5.70% increase year-over-year.
- REPLIGEN CORP interest expense nonoperating for fiscal 2025 was $21.51M, a 3.77% increase from fiscal 2024.
- REPLIGEN CORP interest expense nonoperating for fiscal 2024 was $20.73M, a 728.25% increase from fiscal 2023.
- REPLIGEN CORP interest expense nonoperating for fiscal 2023 was $2.50M, a 115.40% increase from fiscal 2022.
- REPLIGEN CORP interest expense nonoperating for fiscal 2022 was $1.16M, a 89.70% decline from fiscal 2021.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.66M 10-Q · filed 2026-07-29 | $11.24M 10-Q · filed 2026-07-29 | $16.74M derived: sum of 3 quarters · filed 2026-07-29 | $22.15M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $5.58M 10-Q · filed 2026-05-06 | $11.07M derived: sum of 2 quarters · filed 2026-05-06 | $16.49M derived: sum of 3 quarters · filed 2026-05-06 | $21.84M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.91M derived: sum of 2 quarters · filed 2026-02-26 | $16.26M derived: sum of 3 quarters · filed 2026-07-29 | $21.51M 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.41M 10-Q · filed 2025-11-04 | $10.77M derived: sum of 2 quarters · filed 2026-07-29 | $16.02M 10-Q · filed 2025-11-04 | $21.48M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $5.35M 10-Q · filed 2026-07-29 | $10.60M 10-Q · filed 2026-07-29 | $16.07M derived: sum of 3 quarters · filed 2026-07-29 | $21.19M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $5.25M 10-Q · filed 2026-05-06 | $10.71M derived: sum of 2 quarters · filed 2026-05-06 | $15.83M derived: sum of 3 quarters · filed 2026-05-06 | $20.95M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $5.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.58M derived: sum of 2 quarters · filed 2026-02-26 | $15.70M derived: sum of 3 quarters · filed 2026-02-26 | $20.73M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.12M 10-Q · filed 2025-11-04 | $10.24M derived: sum of 2 quarters · filed 2025-11-04 | $15.27M 10-Q · filed 2025-11-04 | $16.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $5.12M 10-Q · filed 2025-08-07 | $10.15M 10-Q · filed 2025-08-07 | $11.42M derived: sum of 3 quarters · filed 2026-02-26 | $11.83M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $5.03M 10-Q · filed 2025-04-29 | $6.30M derived: sum of 2 quarters · filed 2026-02-26 | $6.71M derived: sum of 3 quarters · filed 2026-02-26 | $7.12M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.28M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | $1.68M derived: sum of 2 quarters · filed 2026-02-26 | $2.10M derived: sum of 3 quarters · filed 2026-02-26 | $2.50M 10-K · filed 2026-02-26 |
| 2023-09-30 | $408.00K 10-Q/A · filed 2024-11-18 | $819.00K derived: sum of 2 quarters · filed 2024-11-18 | $1.23M 10-Q/A · filed 2024-11-18 | $1.50M derived: sum of 4 quarters · filed 2025-03-14 |
| 2023-06-30 | $411.00K 10-Q/A · filed 2024-11-18 | $819.00K 10-Q/A · filed 2024-11-18 | $1.09M derived: sum of 3 quarters · filed 2025-03-14 | $1.42M derived: sum of 4 quarters · filed 2025-03-14 |
| 2023-03-31 | $408.00K 10-Q/A · filed 2024-11-18 | $678.00K derived: sum of 2 quarters · filed 2025-03-14 | $1.01M derived: sum of 3 quarters · filed 2025-03-14 | $1.28M derived: sum of 4 quarters · filed 2025-03-14 |
| 2022-12-31 | $270.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | $599.00K derived: sum of 2 quarters · filed 2025-03-14 | $870.00K derived: sum of 3 quarters · filed 2025-03-14 | $1.16M 10-K · filed 2025-03-14 |
| 2022-09-30 | $329.00K 10-Q/A · filed 2024-11-18 | $600.00K derived: sum of 2 quarters · filed 2024-11-18 | $892.00K 10-Q/A · filed 2024-11-18 | |
| 2022-06-30 | $271.00K 10-Q/A · filed 2024-11-18 | $563.00K 10-Q/A · filed 2024-11-18 | ||
| 2022-03-31 | $292.00K 10-Q/A · filed 2024-11-18 | |||
| 2021-12-31 | $11.28M 10-K/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |